Originally posted by pxpaulx I would actually interpret that as follows: Hoya did consider Pentax a risk, but with the profit margin and folding the name/brand into their accounting spreadsheet, this statement appears to indicate they have moved on from considering the camera side to the brand a risk to considering it profitable. In other words, they have now made their decision, and that the favorable decision has been made not to sell.
It reads to me as if Citi are noting the risks to their assessment of Hoya, not of risks to Hoya itself. An upside risk is Hoya's selling Pentax and exiting the business quickly. A downside risk to their analysis is that the process may take longer. There is no mention of a risk of that not happening at all.
Hoya may well divest themselves of the Pentax camera operations even if profitable. It's often easier to sell a profitable operation than a losing operation. If Pentax is profitable now, it's the right time to sell if there is no reason to keep it.
If we look at the numbers again, we see that Pentax (as opposed to Healthcare) has large sales, usually implying a lot of effort to manage the revenue stream. But we look further and find that Pentax is providing a very small share of operating profit.
I look at that and see a division that's a distraction to Hoya. Hoya's management need to aim for margins and profit. That's just what the analysis reports about Hoya's history and corporate goals.
A big consumer unit that has small market share and small margins just does not fit the Hoya model in any way. A distraction. To be flogged around the M&A market with great diligence. And urgency.
Did I miss something?